Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Correction: J&J Sales

Executive Summary

In the story "Private Grünenthal Aims For Leadership In Pain," (Feb. 21, 2011), "The Pink Sheet" incorrectly reported that the smallest drug on a list of reported drug revenues from Johnson & Johnson for 2010 sold $116 million worldwide. That figure was in fact for fourth quarter 2010 sales. Sales of the oral analgesic Nucynta (tapentadol) seem to be below this apparent reporting threshold, but J&J says it is "pleased" with the drug's performance. "In the two years since the product was approved by FDA, health care professionals have written more than half a million prescriptions for Nucynta, as documented in the IMS National Prescription Audit," the firm states. "In addition, in terms of market share (dollars) for short-acting CII opioids, Nucynta has experienced continued growth for the past four quarters, according to IMS National Sales Perspectives."
Advertisement

Related Content

Private Grünenthal Aims For Leadership In Pain
Private Grünenthal Aims For Leadership In Pain

Topics

Advertisement
UsernamePublicRestriction

Register

PS053175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel